Structure Therapeutics Inc ADR 2026年季度报告

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically; every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reportingcompany☐Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The aggregate number of outstanding ordinary shares of the registrant, each with par value $0.0001 per share, as of April 30,2026, was 213,223,549, of which 208,149,459 ordinary shares were held in the form of ADSs. TABLE OF CONTENTS PagePART IItem 1.Financial Statements (Unaudited)7Condensed Consolidated Balance Sheets7Condensed Consolidated Statements of Operations and ComprehensiveLoss8Condensed Consolidated Statements of Shareholders’ Equity9Condensed Consolidated Statements of Cash Flows10Notes to Unaudited Condensed Consolidated Financial Statements11Item 2.Management’s Discussion and Analysis of Financial Condition and Results ofOperations24Item 3.Quantitative and Qualitative Disclosures About Market Risk35Item 4.Controls and Procedures35Part IIItem 1.Legal Proceedings36Item 1A. Risk Factors36Item 2.Unregistered Sales of Equity Securities and Use of Proceeds118Item 3.Defaults Upon Senior Securities118Item 4.Mine Safety Disclosures118Item 5.Other Information119Item 6.Exhibits120Signatures122 CAUTIONARY NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”), contains forward-looking statements.All statements other than statements of historical facts contained in this Quarterly Report areforward-looking statements. In some cases, you can identify forward-looking statements byterms such as “may,” “can,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “could,”“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue”or the negative of these terms or other similar expressions, although not all forward-lookingstatements contain these words. All statements other than statements of historical factscontained in this Quarterly Report, including without limitation statements regarding: ●the timing, progress and results of preclinical studies and clinical studies for our productcandidates, including our product development plans and strategies;●the performance of our third-party service providers, including the impact of datacollection omissions at any of our clinical sites;●the timing, scope and likelihood of regulatory filings and approvals, including finalregulatory approval of our product candidates;●the potential benefits and market opportunity for our product candidates and discoveryplatform;●expectations regarding the size, scope and design of clinical studies;●our plans and strategy with respect to our drug discovery efforts and potential benefits ofour discovery platform;●our manufacturing, commercialization, and marketing plans and strategies;●our plans to hire additional personnel and our ability to attract and retain such personnel;●our estimates of the number of patients who suffer from the diseases we are targetingand potential growth in our target markets;●our expectations regarding the approval and use of our product candidates;●our competitive position and the development and impact of competing therapies thatare or may become available;●expectations regarding future events under collaboration and licensing agreements,including potential future payments, as well as our plans and strategies for entering intofurther collaboration and licensing agreements;●our intellectual property position, including the scope of protection we are able toestablish and maintain for intellectual property rights covering product candidates wemay develop, including the extensions of existing patent terms where available, thevalidity of int